Abaloparatide and paclitaxel combination therapy Improves bone volume and tumor burden in Bone-Metastatic breast cancer.
•Abaloparatide is FDA-approved for osteoporosis but is not well characterized in patients with bone metastases.•Combination abaloparatide and paclitaxel reduced tumor and increased bone volume in an i
APA
Miller JS, Kane JF, et al. (2026). Abaloparatide and paclitaxel combination therapy Improves bone volume and tumor burden in Bone-Metastatic breast cancer.. Journal of bone oncology, 57, 100752. https://doi.org/10.1016/j.jbo.2026.100752
MLA
Miller JS, et al.. "Abaloparatide and paclitaxel combination therapy Improves bone volume and tumor burden in Bone-Metastatic breast cancer.." Journal of bone oncology, vol. 57, 2026, pp. 100752.
PMID
41798079
Abstract
•Abaloparatide is FDA-approved for osteoporosis but is not well characterized in patients with bone metastases.•Combination abaloparatide and paclitaxel reduced tumor and increased bone volume in an intratibial model of cancer in bone.•Abaloparatide alone did not impact tumor burden or bone volume in tumor limb.